First Australian Patients Prescribed Endoca CBD Products
- First Australian patient prescribed THC Global medicinal cannabis product supplied from Endoca's CBD and CBD+CBDa product range
- THC Global is building strong supply chain for imported products in anticipation of launch of THC Global's proprietary manufactured products in 2019
- Endoca CBD+CBDa product range imported by THC Global is GMP Certified
- Ongoing patient and prescriber engagement by THC Global expected to support increased domestic demand
Through completion of this supply, THC Global has verified its supply line from manufacturer through to patient under federal Authorised Prescriber and Special Access Schemes as well as relevant state regulations.
THC Global is currently importing four products from Endoca's range, being its CBD oil in 3% and 15% concentrations, and Endoca's unique CBD+CBDa oils also in 3% and 15% concentrations.
The Company is building patient and prescriber awareness, including sponsoring educational events to highlight the benefits of treatment with medicinal cannabis and the pathways to access product in Australia. As awareness increases within the domestic market, THC Global expects to see corresponding increases in revenue generating product sales.
Documentation which doctors and other prescribers can use to assist in prescribing Endoca's products in Australia under the Authorised Prescriber Scheme and Special Access Schemes can be accessed by registering on the Medicinal Cannabis Medicines Portal (http://mcmp.com.au/).
Enquiries can be directed to THC Global's medical outreach team at firstname.lastname@example.org.
THC Global's Chief Executive Officer, Ken Charteris, commented:
"The ability to secure supply of high-quality GMP certified medicinal cannabis products to domestic patients is a key bridge to implementation of THC Global's 'Farm to Pharma' model.
We continue to build out our domestic infrastructure in Australia under our 'Farm to Pharma' model - research, growing, manufacture and supply."
About THC Global Group Limited
THC Global Group Limited (ASX:THC) (OTCMKTS:HDRPF) (FRA:9TH) operates under a 'Farm to Pharma' pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through existing access schemes. Having secured both a significant growing capacity over two grow sites, and an industry-leading pharmaceuticals biomanufacturing facility with attached testing and product development laboratory, THC Global is in prime position to service both domestic patients and the export market. THC Global's commercial partners operate across four continents, supporting future international growth.
In addition to its core medicinal cannabis business, THC Global owns two Canadian companies, being Crystal Mountain Products and Vertical Canna Inc. Crystal Mountain Products operates a revenue generating global hydroponics retailer and distributor of equipment, material, and nutrients to cannabis growers and producers. Vertical Canna Inc is an investment vehicle through which THC Global intends to build, through acquisitions and strategic partnerships, a vertically integrated Canadian cannabis producer and retailer. Vertical Canna's existing asset portfolio includes a land-holding in Nova Scotia, Canada to be developed into a large-scale cannabis production facility.
THC Global Group Limited